Free 2-Day Shipping on Orders Over $200
GLP-3 R is a triple-agonist analog studied through coordinated engagement of GLP-1, GIP, and glucagon receptors.
GLP-3 R is presented as a next-generation GLP-family triple-agonist peptide. Its defining laboratory feature is not a new “GLP-3” receptor; it is activity across three established class B receptors: GLP-1R, GIPR, and the glucagon receptor.
Cryo-electron microscopy and mutational assays have mapped how triple agonists of this class occupy each receptor and which contacts influence cyclic-AMP signaling. Comparative pharmacology also highlights a central experimental challenge: one peptide can display different potency and efficacy across three receptors, cell systems, and assay endpoints.
This makes GLP-3 R relevant to multi-receptor binding and signaling research. The evidence does not mean a VIVO material was evaluated in the cited work, and it does not establish safety, efficacy, dosing, administration, or an expected outcome in humans or animals.
Peer-reviewed sources for the research summarised above. Vivo summarises published, third-party science and does not conduct or sponsor this research.